SOBI006 / SOBI - LARVOL DELTA

Sobi to buy Novimmune R&D assets, lay off 90 staff (Fierce Pharma) - "Sobi is exiting drug discovery and early research outside of hematology and immunology...The Swedish biopharma unveiled the news alongside the CHF 515 million ($518 million) acquisition of immunology R&D capabilities from Novimmune....Sobi is now looking to divest...preclinical program SOBI006 as part of a shift in its focus toward...immunology assets. The divestitures are part of a reorganization that Sobi expects to shave up to SEK 300 million ($32 million) off its annual costs. Restructuring costs could hit SEK 200 million..."

Commercial • Licensing / partnership